Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | VAX014 |
Synonyms | |
Therapy Description |
VAX014 is bacterial minicell therapeutic comprising E. coli engineered to express Invasin and the bacterial toxin perfringolysin O (PFO), which delivers the toxin to tumor cells expressing Integrin alpha3beta1 or alpha5beta1, potentially resulting in increased tumor cell apoptosis and decreased tumor growth (PMID: 27919942, PMID: 27119118). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
VAX014 | VAX-IP|VAX 014|VAX-014 | VAX014 is bacterial minicell therapeutic comprising E. coli engineered to express Invasin and the bacterial toxin perfringolysin O (PFO), which delivers the toxin to tumor cells expressing Integrin alpha3beta1 or alpha5beta1, potentially resulting in increased tumor cell apoptosis and decreased tumor growth (PMID: 27919942, PMID: 27119118). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05901285 | Phase I | VAX014 | Phase 1 Study of Intratumoral Administration of VAX014 in Subjects With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT03854721 | Phase I | VAX014 | A Phase 1 Study of Intravesical VAX014 for Instillation in Subjects With Non-Muscle Invasive Bladder Cancer | Completed | USA | 0 |